IL33 and systemic lupus erythematosus: Likewise, SLE IC NET-containing supernatants pretreated with anti–IL-33 blocking antibody displayed significantly reduced inteferogenic capacity (Supplemental Figure 5C), thus further supporting the role of the IL-33/ST2L axis on NET-mediated IFN-α production by pDCs.